TECTONIC THERAPEUTIC INC (TECX) Stock Overview
NASDAQ:TECX - US8789721086 - Common Stock
TECX Key Statistics, Chart & Performance
The current stock price of TECX is 25.54 USD. In the past month the price increased by 23.2%. In the past year, price increased by 33.02%.
TECX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.87 | 371.68B | ||
| AMGN | AMGEN INC | 13.19 | 154.89B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
| ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
| INSM | INSMED INC | N/A | 28.77B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
| NTRA | NATERA INC | N/A | 23.09B | ||
| BIIB | BIOGEN INC | 8.26 | 19.38B |
Related stock screener links
About TECX
Company Profile
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). The company is headquartered in Watertown, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).
Company Info
TECTONIC THERAPEUTIC INC
490 Arsenal Way, Suite 210
Watertown MASSACHUSETTS US
Employees: 51
Phone: 13396663320
TECTONIC THERAPEUTIC INC / TECX FAQ
What is the stock price of TECTONIC THERAPEUTIC INC today?
The current stock price of TECX is 25.54 USD. The price decreased by -0.12% in the last trading session.
What is the ticker symbol for TECTONIC THERAPEUTIC INC stock?
The exchange symbol of TECTONIC THERAPEUTIC INC is TECX and it is listed on the Nasdaq exchange.
On which exchange is TECX stock listed?
TECX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TECTONIC THERAPEUTIC INC stock?
14 analysts have analysed TECX and the average price target is 81.31 USD. This implies a price increase of 218.36% is expected in the next year compared to the current price of 25.54. Check the TECTONIC THERAPEUTIC INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TECTONIC THERAPEUTIC INC worth?
TECTONIC THERAPEUTIC INC (TECX) has a market capitalization of 477.85M USD. This makes TECX a Small Cap stock.
How many employees does TECTONIC THERAPEUTIC INC have?
TECTONIC THERAPEUTIC INC (TECX) currently has 51 employees.
What are the support and resistance levels for TECTONIC THERAPEUTIC INC (TECX) stock?
TECTONIC THERAPEUTIC INC (TECX) has a support level at 22.41 and a resistance level at 26.18. Check the full technical report for a detailed analysis of TECX support and resistance levels.
Should I buy TECTONIC THERAPEUTIC INC (TECX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TECX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TECX, evaluating the profitability, health, valuation and growth aspects
- TECTONIC THERAPEUTIC INC (TECX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TECTONIC THERAPEUTIC INC (TECX) Sales and EPS estimates to see what analysts future expectations are.
- TECTONIC THERAPEUTIC INC (TECX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TECTONIC THERAPEUTIC INC (TECX) Insider and Institutional Ownership to learn about the owners and their transactions.
- TECTONIC THERAPEUTIC INC (TECX) Stock Chart to make your own analysis
- TECTONIC THERAPEUTIC INC (TECX) Latest news and press-releases to stay up to date.
Does TECTONIC THERAPEUTIC INC (TECX) stock pay dividends?
TECX does not pay a dividend.
When does TECTONIC THERAPEUTIC INC (TECX) report earnings?
TECTONIC THERAPEUTIC INC (TECX) will report earnings on 2025-11-05, before the market open.
What is the Price/Earnings (PE) ratio of TECTONIC THERAPEUTIC INC (TECX)?
TECTONIC THERAPEUTIC INC (TECX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.04).
What is the Short Interest ratio of TECTONIC THERAPEUTIC INC (TECX) stock?
The outstanding short interest for TECTONIC THERAPEUTIC INC (TECX) is 18.8% of its float. Check the ownership tab for more information on the TECX short interest.
TECX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to TECX. When comparing the yearly performance of all stocks, TECX is one of the better performing stocks in the market, outperforming 84.05% of all stocks.
TECX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TECX. While TECX seems to be doing ok healthwise, there are quite some concerns on its profitability.
TECX Financial Highlights
Over the last trailing twelve months TECX reported a non-GAAP Earnings per Share(EPS) of -4.04. The EPS increased by 55.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.34% | ||
| ROE | -23.25% | ||
| Debt/Equity | 0 |
TECX Forecast & Estimates
14 analysts have analysed TECX and the average price target is 81.31 USD. This implies a price increase of 218.36% is expected in the next year compared to the current price of 25.54.